Overall survival outcome in the trials could not be satisfactorily explained by differences in the incidence of thrombosis and related complications ng between those given recombinant human erythropoietin and those in the control group. lo A systematic review has also been performed involving more than 9000 cancer patients participating in 57 clinical trials.